Methods for processing or analyzing sample of thyroid tissue
The present disorders disclosure provides method for processing or analyzing a sample of thyroid tissue of a subject, to generate a classification of the sample of thyroid tissue as positive or negative for thyroid cancer. The present disclosure also provides algorithms and methods of classifying cancer, for example, thyroid cancer, methods of determining molecular profiles, and methods of analyzing results, which may be used to provide a diagnosis.
1. A method for processing or analyzing a sample of thyroid tissue of a subject, comprising:
(a) obtaining said sample of thyroid tissue of said subject, wherein said subject has or is suspected of having thyroid cancer, and wherein said sample of thyroid tissue comprises gene expression products;
(b) subjecting a first portion of said sample of thyroid tissue to cytological testing that indicates that said first portion of said sample of thyroid tissue is indeterminate;
(c) upon identifying said first portion of said sample of thyroid tissue as indeterminate, assaying by sequencing, array hybridization, or nucleic acid amplification, said gene expression products from a second portion of said sample of thyroid tissue, to yield a data set including data corresponding to gene expression product levels;
(d) in a programmed computer, inputting said data including said gene expression product levels from (c) to a trained algorithm to generate a classification of said sample of thyroid tissue as positive or negative for said thyroid cancer at an accuracy of at least 90%, wherein said trained algorithm is trained with a plurality of training samples, and wherein said sample of thyroid tissue is independent of said plurality of training samples; and
(e) electronically outputting a report that identifies said classification of said sample of thyroid tissue as positive or negative for said thyroid cancer.
2. The method of claim 1 , wherein said gene expression products include messenger ribonucleic acid (mRNA).
3. The method of claim 2 , wherein said mRNA has a ribonucleic acid integrity number (RIN) of 2.0 or more.
4. The method of claim 2 , wherein a portion of said mRNA is used for multi-gene microarray analysis, and wherein said sample of thyroid tissue has an RIN of equal to or less than 5.0.
5. The method of claim 2 , wherein said assaying of (b) comprises subjecting complementary deoxyribonucleic acid (cDNA) molecules, generated from amplification of said mRNA, to sequencing to yield said data set.
6. The method of claim 5 , wherein said sequencing is high throughput sequencing.
7. The method of claim 5 , wherein said sequencing is partial or whole genome sequencing.
8. The method of claim 1 , wherein said assaying comprises using one or more of the following: microarray, SAGE, blotting, reverse transcription, or quantitative polymerase chain reaction (PCR).
9. The method of claim 1 , wherein said trained algorithm is trained with multiple datasets of gene expression product levels obtained from said plurality of training samples.
10. The method of claim 1 , wherein said sample of thyroid tissue is benign for said thyroid cancer, and wherein said trained algorithm does not classify said sample of thyroid tissue as positive for said thyroid cancer.
11. The method of claim 10 , wherein said trained algorithm classifies said sample of thyroid tissue as negative for said thyroid cancer.
12. The method of claim 1 , wherein said sample of thyroid tissue is malignant for said thyroid cancer, and wherein said trained algorithm classifies said sample of thyroid tissue as positive for said thyroid cancer.
13. The method of claim 1 , wherein said trained algorithm generates said classification at an accuracy of at least about 90% for at least two subtypes of cancer.
14. The method of claim 1 , wherein said trained algorithm generates said classification at a specificity of at least about 80%.
15. The method of claim 14 , wherein said trained algorithm generates said classification at a specificity of at least about 90%.
16. The method of claim 1 , wherein said trained algorithm generates said classification at a sensitivity of at least about 70%.
17. The method of claim 16 , wherein said trained algorithm generates said classification at a sensitivity of at least about 80%.
18. The method of claim 1 , wherein said sample of thyroid tissue is a fine needle aspirate sample of thyroid tissue.
19. The method of claim 18 , wherein, (i) when said classification identifies said sample of thyroid tissue as negative for said thyroid cancer, obtaining another sample of thyroid tissue from said subject and repeating (b)-(e) to monitor a change over time in said gene expression product levels, or (ii) when said classification identifies said sample of thyroid tissue as positive for said thyroid cancer, treating said subject by a thyroidectomy.
20. The method of claim 1 , wherein said plurality of training samples comprises cytologically indeterminate samples.
21. The method of claim 1 , wherein said plurality of training samples comprises fine needle aspirate (FNA) samples.
22. The method of claim 21 , wherein said plurality of training samples comprises greater than 300 FNA samples.
23. The method of claim 21 , wherein said plurality of training samples comprises surgical biopsy samples.
24. The method of claim 1 , wherein said first portion is different from said second portion.
25. The method of claim 1 , further comprising, upon identifying said first portion of said sample of thyroid tissue as indeterminate, (i) identifying one or more variants in a third portion of said sample of thyroid tissue, and (ii) using said one or more variants and said gene expression product levels to generate said classification of said sample of thyroid tissue as positive or negative for said thyroid cancer at an accuracy of at least 90%.
26. The method of claim 25 , wherein said third portion is the same as said second portion.
27. The method of claim 1 , wherein said plurality of training samples comprises greater than 500 thyroid tissue samples.
28. The method of claim 27 , wherein said plurality of training samples comprises greater than 300 fine needle aspirate samples.
29. The method of claim 1 , wherein said plurality of training samples comprises surgical biopsy samples.
30. The method of claim 1 , wherein said sample of thyroid tissue is not benign or malignant, and wherein said trained algorithm classifies said sample of thyroid tissue as normal.